Drug Trial Radar · NCT04192500
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
Last checked: Nov 19, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Dec 11, 2019
Primary completion
Sep 7, 2020
Study completion Sep 7, 2020
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- University Ghent
- First posted
- Dec 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and expand immunogenicity and safety data to adults through age 65.
Conditions
- Influenza
Interventions
OVX836Biological
One single administration intramuscularly at Day 1.
Quadrivalent seasonal influenza vaccine (Influvac TetraTM)Biological
One single administration intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- NP-specific IFNγ T-cell increase measured by ELISPOT at Day 8 versus pre-injection baseline (Day 1) in the pooled age strataTime frame: at Day 8 versus pre-injection baseline (Day 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Vaccinology (CEVAC)
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.